Læknablaðið - 15.12.1996, Síða 42

866
LÆKNABLAÐIÐ 1996; 82
benign prostatic obstruction. J Urol 1968; 99: 639-45.
3. Guess HA. Benign prostatic hyperplasia: antecedents
and natural history. Epidemiol Rev 1992; 14: 131-53.
4. Scott WW. What makes prostate grow? J Urol 1953; 70:
477-88.
5. Andersen JT. Prostatism, clinical, urodynamic and ra-
diological aspects. Neurol Urodyn 1982; 1: 241-93.
6. Blandy JP, LyttonB, (eds). The Prostate. London: But-
terworths, 1986.
7. Wasson JH, Reda DJ, Bruskewik RC, Elinson J, Keller
AM, Henderson WG. A comparsion of transurethral
surgery with watchful waiting for moderate symptoms of
benign prostatic hyperplasia. N Engl J Med 1995; 332:
75-9.
8. Bruchovsky N, Wilson JD. The conversion of testoster-
one to 5alpha-androstane-17beta-ol-3 one by rat pros-
tate in vivo and in vitro. J Biol Chem 1968; 243: 2012-21.
9. Stoner E. Three-year safety and efficacy data on the use
of finasteride in the treatment of benign prostatic hy-
perplasia. Urology 1994; 43: 284-94.
10. Beisland HO, Binkowitz B, Brekkan E, Ekman P,
Kontturi M. Lehtonen T, et al. Scandinavian clinical
study of finasteride in the treatment of benign prostatic
hyperplasia. Eur Urol 1992; 22: 271-7.
11. Gormley GJ, Stoner E, Bruskewik RC, Imperato-
McGinley J, Walsh PC, McConnell JD, et al. The effect
of finasteride in men with benign prostatic hyperplasia.
The Finasteride Study Group. N Engl J Med 1992; 327:
1185-91.
12. Finasteride Study Group and Stoner E. Finasteride
(MK-906) in the treatment of benign prostatic hyperpla-
sia. Prostate 1993; 22: 291-9.
13. Ekman P. Efficacy of placebo in the treatment of benign
prostatic hyperplasia. In: Puppo P, ed. Contemporary
BPH Management. Bologna: Mundez Editore, 1993:
35-41.
14. Boyarsky S, Jones G, Paulson DF, Prout GR Jr. A new
look at bladder neck obstruction by the Food and Drug
Administration regulators: guide lines for investigation
of benign prostatic hypertrophy. Trans Am Assoc Geni-
tourin Surg 1976; 68: 29-32.
15. Bologenese JA, Kozloff RC, Kunik SC, Grino PB, Pa-
trick DL, Stoner E. Validation of a symptoms question-
naire for benign prostatic hyperplasia. Prostate 1992; 21:
247-54.
16. Grino PB, Bruskewitz RC, Blaivas JG, Siroky MB,
Andersen JT, Cook T, et al. Maximum urinary flow rate
by uroflowmetry: automatic or visual interpretation. J
Urol 1993; 149: 339^1.
17. Coombes GM, Millard RJ. Accuracy of portable ultra-
sound scanning in the measurement of residual urine
volume. J Urol 1994; 152: 2083-5.
18. Girman CJ, Jacobsen SJ, Guess HA, Oesterling JE,
Chute CG, Panser LA, et al. Natural history of prosta-
tism: relationship among symptoms, prostate volume
and peak urinary flow rate. J Urol 1995: 153: 1510-5.
19. Benign Prostatic Hyperplasia Guideline Panel: Benign
Prostatic Hyperplasia: Diagnosis and Treatment. Wash-
ington, DC: US Government Printing Office, 1994:
73-5.
Viðauki
í skandinavíska rannsóknarhópnum um góðkynja stækkun á
blöðruhálskirtli eru þessir:
Danmörk: Andersen JT, Bodker A, Vedel O, Hvidovre
Hospital; Nordling J, Poulsen AL, Schou J, Herlev Syge-
hus; Hvidt V, Hansen JB, Bispebjerg Hospital; Meyhoff
HH, Eldrup J, Hartwell D, Hilleröd Sygehus; Colstrup H,
Lyngdorf P, Gentofte Amts Sygehus; Holm Nielsen A,
Esbjerg Centralsygehus; Larsen E, Næstved Centralsyge-
hus; Wolf H, Skejby Sygehus; Walter S, Larsen EH, Al-
borg Sygehus; Thybo E, Mommsen S, Brok KE, Odense
Sygehus; Palm L, Roskilde Sygehus; Genster H, Ander-
sen M, Spnderborg Sygehus.
Finnland: Kauppinen P. Rauvala M, Lappi Central Hospi-
tal; Kontturi M, Hakkinen J, Oulu University Central
Hospital; Tammela T, Tainio H. Tampere University Ho-
spital; Hynninen O, Lahti City Hospital; Tiitinen J, Leh-
toranta K. Paijat-Hame Central Hospital: Ala-Opas M.
Kanta-Hame Central Hospital; Lehtonen T, Perttila I,
Petas A, Helsinki University Central Hospital; Rintala E,
Malmi Hospital; Salminen R, Lohja Hospital; Juusela H,
Jorvi Hospital; Hansson E, von Wendt R. Vaasa Central
Hospital; Tuhkanen K, Talja M, Kuopio University Ho-
spital; Nurmi M, Puntala P, Turku University Central
Flospital; Permi J, Puolakka VM, Etela-Kaijala Central
Hospital; Viitanen J, Pohjois-Karjala Central Hospital.
ísland: Gíslason Þ, St. Jósefsspítali; Einarsson GV, Land-
spítalinn.
Noregur: Eri LM, Ulleval Hospital; Karlsen S, Aker Hospi-
tal; Holme P, Akershus Central Hospital; Sivertsen SM,
Hedmark Central Hospital; Steinsvik E, Servoll E, Buske-
rud Central Hospital; Urnes T. Malme PA, Vestfold Cen-
tral Hospital; Bjerklund Johansen TE, Omland H, Nagel-
hus J, Telemark Central Hospital; Kloster SE, Skjeg-
gestad O, Rogaland Central Hospital; Vada K, Innherred
Hospital; Morgensen R, Nordland Central Hospital.
Svíþjóð: Nyberg G. Pettersson G, Wedman L. Boden Hospi-
tal; Bratell S, Folmerz P, Zackrisson B. Borás Hospital;
Dahlgren K, Tillegard A, Falun Hospital; Aus G, Berg-
dahl S, Hugosson J, Östra Hospital Göteborg; Holmquist
B, Ornehufvudsgatan Göteborg; Ek A, Rademark C, Kri-
stiansen P, Helsingborg Hospital: Hermansson CG. Pe-
dersen K, Oscarsson C, Rybov County Hospital Jönköp-
ing; Kihl B, Olsson JO, Karlstad Central Hospital; Nelvin
L, Leissner KH, Lundstam S, Mölndal Hospital; Hjert-
berg H, Varenhorst E, Norrköping Hospital; Andersson
SO. Johansson JE, Windahl T. Swartz R. Regional Hospi-
tal Örebro; Ahlberg B,Gedda S, Östersund Hospital; An-
derstrom C, Eddeland A, Hansson R, Stroberg P. Skövde
Central Hospital; Adolfsson J, Ekman P, Karolinska Ho-
spital Stockholm; Bauer P, Medical Center Vallingby
Stockholm; Kleist H, Storm B, Trollhattan Hospital;
Ranch T, Stravsnes H, Uddevalla Hospital; Brekkan E,
University Hospital Uppsala; Eklund T, Karlberg L, Va-
sterás Hospital.
Gagnaúrvinnsla: Malice MP (Merck Research Laborato-
ries).
Tækniþjónusta, Merck Sharp & Dohme: Bronee V, Wen-
nerlund P, Eriksson LO, Aaserud E, Lehmussaari J, Suo-
min R, Gabriel MA.